Literature DB >> 15124758

Multiple sclerosis attacks are associated with picornavirus infections.

John D Kriesel1, Andrea White, Frederick G Hayden, S L Spruance, Jack Petajan.   

Abstract

Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system, which often follows a relapsing-remitting (RR) course with discrete attacks. MS attacks have been associated with upper respiratory infections (URIs), but the specific viruses responsible have not been identified. We studied a cohort of 16 RRMS patients experiencing URI and followed them for clinically identifiable attacks. The viral causes of 21 separate URIs were investigated using culture and polymerase chain reaction (PCR) of nasal swab specimens, and by serology. Sibleys 'at-risk' period for MS attacks, beginning two weeks before and continuing for five weeks after a URI, was used for the analysis. Seven of the nine (78%) URIs due to picornaviruses were associated with an MS attack during the at-risk period. By contrast, only two of 12 (17%) picornavirus-negative URIs were associated with an MS attack (P = 0.01). The possible role of picornaviruses in the pathogenesis of MS deserves further study.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15124758     DOI: 10.1191/1352458504ms1005oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  12 in total

1.  Measurement of mucociliary clearance in the patients with multiple sclerosis.

Authors:  Ender Sahin; Mehmet Hamamcı; Yunus Kantekin
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-11-09       Impact factor: 2.503

Review 2.  Multiple sclerosis: autoimmunity and viruses.

Authors:  Matthew F Cusick; Jane E Libbey; Robert S Fujinami
Journal:  Curr Opin Rheumatol       Date:  2013-07       Impact factor: 5.006

3.  Influenza infection triggers disease in a genetic model of experimental autoimmune encephalomyelitis.

Authors:  Stephen Blackmore; Jessica Hernandez; Michal Juda; Emily Ryder; Gregory G Freund; Rodney W Johnson; Andrew J Steelman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-10       Impact factor: 11.205

Review 4.  Theiler's murine encephalomyelitis virus infection of SJL/J and C57BL/6J mice: Models for multiple sclerosis and epilepsy.

Authors:  Ana Beatriz DePaula-Silva; Tyler J Hanak; Jane E Libbey; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2017-02-12       Impact factor: 3.478

5.  Targeting myelin proteolipid protein to the MHC class I pathway by ubiquitination modulates the course of experimental autoimmune encephalomyelitis.

Authors:  Diethilde J Theil; Jane E Libbey; Fernando Rodriguez; J Lindsay Whitton; Ikuo Tsunoda; Tobias J Derfuss; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2008-11-15       Impact factor: 3.478

6.  Virus-induced CD8+ T cells accelerate the onset of experimental autoimmune encephalomyelitis: implications for how viral infections might trigger multiple sclerosis exacerbations.

Authors:  Emily K Rainey-Barger; Pennelope K Blakely; Amanda K Huber; Benjamin M Segal; David N Irani
Journal:  J Neuroimmunol       Date:  2013-04-18       Impact factor: 3.478

7.  Viral pre-challenge increases central nervous system inflammation after intracranial interleukin-1β injection.

Authors:  Yvonne Couch; Andrew E Davis; Inês Sá-Pereira; Sandra J Campbell; Daniel C Anthony
Journal:  J Neuroinflammation       Date:  2014-10-17       Impact factor: 8.322

Review 8.  Potential triggers of MS.

Authors:  Jane E Libbey; Robert S Fujinami
Journal:  Results Probl Cell Differ       Date:  2010

Review 9.  Infection as an Environmental Trigger of Multiple Sclerosis Disease Exacerbation.

Authors:  Andrew J Steelman
Journal:  Front Immunol       Date:  2015-10-19       Impact factor: 7.561

10.  Factors associated with relapses in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis.

Authors:  Yao Xie; Ziyu Tian; Fang Han; Shibing Liang; Ying Gao; Dahua Wu
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.